TY - JOUR
T1 - Two susceptibility loci identified for prostate cancer aggressiveness
AU - African Ancestry Prostate Cancer GWAS Consortium
AU - Berndt, Sonja I.
AU - Wang, Zhaoming
AU - Yeager, Meredith
AU - Alavanja, Michael C.
AU - Albanes, Demetrius
AU - Amundadottir, Laufey
AU - Andriole, Gerald
AU - Beane Freeman, Laura
AU - Campa, Daniele
AU - Cancel-Tassin, Geraldine
AU - Canzian, Federico
AU - Cornu, Jean Nicolas
AU - Cussenot, Olivier
AU - Diver, W. Ryan
AU - Gapstur, Susan M.
AU - Grönberg, Henrik
AU - Haiman, Christopher A.
AU - Henderson, Brian
AU - Hutchinson, Amy
AU - Hunter, David J.
AU - Key, Timothy J.
AU - Kolb, Suzanne
AU - Koutros, Stella
AU - Kraft, Peter
AU - Le Marchand, Loic
AU - Lindström, Sara
AU - Machiela, Mitchell J.
AU - Ostrander, Elaine A.
AU - Riboli, Elio
AU - Schumacher, Fred
AU - Siddiq, Afshan
AU - Stanford, Janet L.
AU - Stevens, Victoria L.
AU - Travis, Ruth C.
AU - Tsilidis, Konstantinos K.
AU - Virtamo, Jarmo
AU - Weinstein, Stephanie
AU - Wilkund, Fredrik
AU - Xu, Jianfeng
AU - Lilly Zheng, S.
AU - Yu, Kai
AU - Wheeler, William
AU - Zhang, Han
AU - Sampson, Joshua
AU - Black, Amanda
AU - Jacobs, Kevin
AU - Hoover, Robert N.
AU - Tucker, Margaret
AU - Chanock, Stephen J.
AU - Ingles, Sue A.
N1 - Publisher Copyright:
© 2015 Macmillan Publishers Limited. All rights reserved.
PY - 2015/5/5
Y1 - 2015/5/5
N2 - Most men diagnosed with prostate cancer will experience indolent disease; hence, discovering genetic variants that distinguish aggressive from nonaggressive prostate cancer is of critical clinical importance for disease prevention and treatment. In a multistage, case-only genome-wide association study of 12,518 prostate cancer cases, we identify two loci associated with Gleason score, a pathological measure of disease aggressiveness: rs35148638 at 5q14.3 (RASA1, P=6.49 × 10-9) and rs78943174 at 3q26.31 (NAALADL2, P=4.18 × 10-8). In a stratified case-control analysis, the SNP at 5q14.3 appears specific for aggressive prostate cancer (P=8.85 × 10-5) with no association for nonaggressive prostate cancer compared with controls (P=0.57). The proximity of these loci to genes involved in vascular disease suggests potential biological mechanisms worthy of further investigation.
AB - Most men diagnosed with prostate cancer will experience indolent disease; hence, discovering genetic variants that distinguish aggressive from nonaggressive prostate cancer is of critical clinical importance for disease prevention and treatment. In a multistage, case-only genome-wide association study of 12,518 prostate cancer cases, we identify two loci associated with Gleason score, a pathological measure of disease aggressiveness: rs35148638 at 5q14.3 (RASA1, P=6.49 × 10-9) and rs78943174 at 3q26.31 (NAALADL2, P=4.18 × 10-8). In a stratified case-control analysis, the SNP at 5q14.3 appears specific for aggressive prostate cancer (P=8.85 × 10-5) with no association for nonaggressive prostate cancer compared with controls (P=0.57). The proximity of these loci to genes involved in vascular disease suggests potential biological mechanisms worthy of further investigation.
UR - http://www.scopus.com/inward/record.url?scp=84929000290&partnerID=8YFLogxK
U2 - 10.1038/ncomms7889
DO - 10.1038/ncomms7889
M3 - Article
C2 - 25939597
AN - SCOPUS:84929000290
SN - 2041-1723
VL - 6
JO - Nature communications
JF - Nature communications
M1 - 6889
ER -